奈达铂联合替吉奥治疗晚期食管癌的疗效观察

目的观察奈达铂与替吉奥联合治疗晚期食管癌的临床疗效。方法 26例晚期食管癌患者应用奈达铂80～100mg/m2加入生理盐水500ml中静脉滴注2h,d1;替吉奥80mg/(m2.d),分2次,餐后口服,d1～d14。21d为1个周期,至少使用2个周期后评价疗效。结果平均每例患者治疗4.69个周期,完全缓解(CR)0例,部分缓解(PR)13例(50%),稳定(NC)7例(26.92%),进展(PD)6例(23.08%),总有效率(RR)为50%。主要不良反应为骨髓抑制。结论奈达铂联合替吉奥治疗晚期食管癌疗效较好,不良反应亦较小,值得临床推广应用。

The observation of the effect of nedaplatin combined with gimeracil and oteracil porassium capsules in the treatment of advanced esophageal carcinoma

Objective Observing the clinical effect of curing advanced cancer of the esophagus by using nedaplatin joins gimeracil and oteracil porassium capsules.Methods 26 patients of advanced cancer of the esophagus take Nedaplatin for the 80~100mg/m2 by joining Normal Saline 500ml with intravenous drip 2h,d1;and take gimeracil and oteracil porassium capsules for the 80mg/(m2·d) in two times,preferably with a meal d1~d14.21d for 1 period,then evaluate the curative effect at least two periods later.Results Each patients takes 4.69 cycles on average,complete remission(CR) with 0 cases,part remission with(PR) 13 cases(50%),stable(NC)7 cases(26.92%),progress(PD) 6 patients(23.08%),the total effective rate(RR) of 50%.The major adverse reaction is bone marrow depression.Conclusion The curative effect of curing advanced cancer of the esophagus by using nedaplatin joins gimeracil and oteracil porassium capsules is good,and the bad reaction is also smaller,it deserves to be clinical application.